CHO Cell S100A Gene Cluster Integration for Stable Protein Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing therapeutic proteins in Chinese Hamster Ovary (CHO) cells rely on random integration, which leads to heterogeneity and instability in protein expression due to unpredictable chromosomal positioning effects, making it difficult to identify suitable genomic loci for high-yield and stable production.
Innovation Solution
Stable integration of heterologous polynucleotides into the S100A gene cluster, specifically upstream or downstream of the S100A3/A4/A5/A6 main gene cluster, using site-specific DNA editing enzymes like zinc finger nucleases to achieve predictable and high-level production of therapeutic proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If random integration is used for expression vectors in CHO cells, then a large number of clones can be generated, but heterogeneity in protein expression and instability occur due to unpredictable chromosomal positioning effects
Solution Approach 1:
The patent applies preliminary action by pre-identifying and characterizing specific genomic loci (S100A gene cluster regions) that are known to support high-level stable expression before performing integration. This allows researchers to target these predetermined safe harbor sites rather than relying on random integration followed by extensive screening, thereby achieving both high productivity and reliability from the outset.
2Ease of manufacture
If random integration is used, then cell line development can proceed without predetermined target sites, but extensive screening of clones is required to identify high producer cells
Solution Approach 1:
The patent performs preliminary characterization of genomic loci to identify safe harbor sites with proven high-expression capabilities. By having these target sites predetermined and validated beforehand, the method eliminates the need for extensive post-integration screening, significantly reducing time loss while maintaining ease of manufacture through targeted integration strategies.
3Reliability
If targeted integration into predetermined genomic loci is used, then homogeneity and stability of expression are improved, but identification of suitable genomic loci becomes more complex
Solution Approach 1:
The patent resolves this contradiction by performing preliminary identification and comprehensive characterization of genomic loci in advance. The S100A gene cluster regions were pre-screened and validated for their expression-supporting properties, creating a known set of safe harbor sites. This upfront work simplifies subsequent targeted integration efforts, as researchers can directly target these characterized regions without needing to perform complex real-time analysis during the integration process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in homogeneous and stable expression of therapeutic proteins, significantly reducing the need for extensive screening and increasing the proportion of high-producing cells, thereby enhancing the efficiency of biopharmaceutical protein production.
Implementation Method 1
using site-specific DNA editing enzymes like zinc finger nucleases to achieve predictable and high-level production of therapeutic proteins
Data Source
AI summary
The present invention relates to the identification of a genomic integration site for heterologous polynucleotides in Chinese Hamster Ovary (CHO) cells resulting in high RNA and/or protein production. More specifically it relates to CHO cells comprising at least one heterologous polynucleotide stably integrated into the S100A gene cluster of the CHO genome and to methods for the production of said CHO cells. Further, the invention relates to a method for the production of a protein of interest using said CHO cell and to the use of said CHO cell for producing a protein of interest at high yield. Integration within these specific target regions leads to reliable, stable and high yielding production of an RNA and/or protein of interest, encoded by the heterologous polynucleotide.